Joshua D Niznik1,2,3, Jacob N Hunnicutt1, Xinhua Zhao1, Maria K Mor1,4, Florentina Sileanu1, Sherrie L Aspinall1,5,6, Sydney P Springer1,7, Mary J Ersek1,8,9, Walid F Gellad1,10, Loren J Schleiden1,6, Joseph T Hanlon1,10,11, Joshua M Thorpe1,3, Carolyn T Thorpe1,3. 1. Center for Health Equity Research and Promotion, Veterans Affairs (VA) Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. 2. Division of Geriatric Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina. 3. Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina. 4. Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania. 5. VA Center for Medication Safety, Hines, Illinois. 6. University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania. 7. University of New England College of Pharmacy, Portland, Maine. 8. Veterans Experience Center; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania. 9. School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania. 10. Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 11. Geriatric Research Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania.
Abstract
OBJECTIVES: Many older adults with limited life expectancy and/or advanced dementia (LLE/AD) are potentially overtreated for diabetes and may benefit from deintensification. Our aim was to examine the incidence and predictors of diabetes medication deintensification in older Veterans with LLE/AD who were potentially overtreated at admission to Veterans Affairs (VA) nursing homes (community living centers [CLCs]). DESIGN: Retrospective cohort study using linked VA and Medicare clinical/administrative data and Minimum Data Set assessments. SETTING: VA CLCs. PARTICIPANTS: A total of 6960 Veterans with diabetes and LLE/AD admitted to VA CLCs in fiscal years 2009 to 2015 with hemoglobin (Hb)A1c measured within 90 days of admission. MEASUREMENTS: We evaluated treatment deintensification (discontinuation or dose reduction for a consecutive 7-day period) among residents who were potentially overtreated (HbA1c ≤7.5% and receiving hypoglycemic medications). Competing risk models assessed 90-day cumulative incidence of deintensification. RESULTS: More than 40% (n = 3056) of Veteran CLC residents with diabetes were potentially overtreated. The cumulative incidence of deintensification at 90 days was 45.5%. Higher baseline HbA1c values were associated with a lower likelihood of deintensification (e.g., HbA1c 7.0-7.5% vs <6.0%; adjusted risk ratio [aRR] = .57; 95% confidence interval [CI] = .50-.66). Compared with non-sulfonylurea oral agents (e.g., metformin), other treatment regimens were more likely to be deintensified (aRR = 1.31-1.88), except for basal insulin (aRR = .59; 95% CI = .52-.66). The only resident factor associated with increased likelihood of deintensification was documented end-of-life status (aRR = 1.12; 95% CI = 1.01-1.25). Admission from home/assisted living (aRR = .85; 95% CI = .75-.96), obesity (aRR = .88; 95% CI = .78-.99), and peripheral vascular disease (aRR = .90; 95% CI = .81-.99) were associated with decreased likelihood of deintensification. CONCLUSION: Deintensification of treatment regimens occurred in less than one-half of potentially overtreated Veterans and was more strongly associated with low HbA1c values and use of medications with high risk for hypoglycemia, rather than other resident characteristics. J Am Geriatr Soc 68:736-745, 2020.
OBJECTIVES: Many older adults with limited life expectancy and/or advanced dementia (LLE/AD) are potentially overtreated for diabetes and may benefit from deintensification. Our aim was to examine the incidence and predictors of diabetes medication deintensification in older Veterans with LLE/AD who were potentially overtreated at admission to Veterans Affairs (VA) nursing homes (community living centers [CLCs]). DESIGN: Retrospective cohort study using linked VA and Medicare clinical/administrative data and Minimum Data Set assessments. SETTING:VA CLCs. PARTICIPANTS: A total of 6960 Veterans with diabetes and LLE/AD admitted to VA CLCs in fiscal years 2009 to 2015 with hemoglobin (Hb)A1c measured within 90 days of admission. MEASUREMENTS: We evaluated treatment deintensification (discontinuation or dose reduction for a consecutive 7-day period) among residents who were potentially overtreated (HbA1c ≤7.5% and receiving hypoglycemic medications). Competing risk models assessed 90-day cumulative incidence of deintensification. RESULTS: More than 40% (n = 3056) of Veteran CLC residents with diabetes were potentially overtreated. The cumulative incidence of deintensification at 90 days was 45.5%. Higher baseline HbA1c values were associated with a lower likelihood of deintensification (e.g., HbA1c 7.0-7.5% vs <6.0%; adjusted risk ratio [aRR] = .57; 95% confidence interval [CI] = .50-.66). Compared with non-sulfonylurea oral agents (e.g., metformin), other treatment regimens were more likely to be deintensified (aRR = 1.31-1.88), except for basal insulin (aRR = .59; 95% CI = .52-.66). The only resident factor associated with increased likelihood of deintensification was documented end-of-life status (aRR = 1.12; 95% CI = 1.01-1.25). Admission from home/assisted living (aRR = .85; 95% CI = .75-.96), obesity (aRR = .88; 95% CI = .78-.99), and peripheral vascular disease (aRR = .90; 95% CI = .81-.99) were associated with decreased likelihood of deintensification. CONCLUSION: Deintensification of treatment regimens occurred in less than one-half of potentially overtreated Veterans and was more strongly associated with low HbA1c values and use of medications with high risk for hypoglycemia, rather than other resident characteristics. J Am Geriatr Soc 68:736-745, 2020.
Authors: Christine T Cigolle; Kenneth M Langa; Mohammed U Kabeto; Zhiyi Tian; Caroline S Blaum Journal: Ann Intern Med Date: 2007-08-07 Impact factor: 25.391
Authors: Natali Jokanovic; Edwin C K Tan; Michael J Dooley; Carl M Kirkpatrick; J Simon Bell Journal: J Am Med Dir Assoc Date: 2015-04-11 Impact factor: 4.669
Authors: Seth F Einterz; Robin Gilliam; Feng Chang Lin; J Marvin McBride; Laura C Hanson Journal: J Am Med Dir Assoc Date: 2014-02-06 Impact factor: 4.669
Authors: Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Vivian A Fonseca; Jeffrey R Garber; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez Journal: Endocr Pract Date: 2018-01-17 Impact factor: 3.443
Authors: Joshua D Niznik; Song Zhang; Maria K Mor; Xinhua Zhao; Mary Ersek; Sherrie L Aspinall; Walid F Gellad; Joshua M Thorpe; Joseph T Hanlon; Loren J Schleiden; Sydney Springer; Carolyn T Thorpe Journal: J Am Geriatr Soc Date: 2018-10-18 Impact factor: 5.562
Authors: Carolyn T Thorpe; Walid F Gellad; Chester B Good; Sijian Zhang; Xinhua Zhao; Maria Mor; Michael J Fine Journal: Diabetes Care Date: 2015-01-15 Impact factor: 19.112
Authors: M Sue Kirkman; Vanessa Jones Briscoe; Nathaniel Clark; Hermes Florez; Linda B Haas; Jeffrey B Halter; Elbert S Huang; Mary T Korytkowski; Medha N Munshi; Peggy Soule Odegard; Richard E Pratley; Carrie S Swift Journal: Diabetes Care Date: 2012-10-25 Impact factor: 19.112
Authors: Medha N Munshi; Hermes Florez; Elbert S Huang; Rita R Kalyani; Maria Mupanomunda; Naushira Pandya; Carrie S Swift; Tracey H Taveira; Linda B Haas Journal: Diabetes Care Date: 2016-02 Impact factor: 19.112
Authors: Joshua D Niznik; Xinhua Zhao; Florentina Slieanu; Maria K Mor; Sherrie L Aspinall; Walid F Gellad; Mary Ersek; Ryan P Hickson; Sydney P Springer; Loren J Schleiden; Joseph T Hanlon; Joshua M Thorpe; Carolyn T Thorpe Journal: Diabetes Care Date: 2022-07-07 Impact factor: 17.152
Authors: Enrico Longato; Barbara Di Camillo; Giovanni Sparacino; Angelo Avogaro; Gian Paolo Fadini Journal: Cardiovasc Diabetol Date: 2022-08-22 Impact factor: 8.949
Authors: Anastasia-Stefania Alexopoulos; Anna R Kahkoska; Virginia Pate; Marie C Bradley; Joshua Niznik; Carolyn Thorpe; Til Stürmer; John Buse Journal: JAMA Netw Open Date: 2021-11-01